Investors claim Novo Nordisk misled the market about CagriSema's tolerability, after disappointing clinical trial results wiped billions off its market cap.
Read full articleWhy shareholders are suing Novo Nordisk over next-generation weight-loss drug
Written on 07/29/2026

